When do you consider a biologic as a first-line treatment for psoriasis?
Featuring Raj Chovatiya, MD, PhD, MSCI |
Clinical Associate Professor, Rosalind Franklin University Chicago Medical School, Founder and Director, Center for Medical Dermatology and Immunology Research
Chicago, IL
More from this series
Psoriasis
What are the most common adverse reactions seen with ixekizumab?
Featuring Raj Chovatiya, MD, PhD, MSCI
Psoriasis
What factors should be considered when determining optimal treatment duration for ixekizumab in patients with psoriasis?
Featuring Raj Chovatiya, MD, PhD, MSCI
Related CME
1 Credit
Click to save this course
Psoriasis
CME
DermInsider - VGR Session 2
Mastering Psoriasis Management With Medicare
Release Date
March 27, 2025
1 Credit
Click to save this course
Psoriasis
CME
FC24: The Comorbidities of Psoriasis: What Clinicians Need to Know to Optimize Care: An Online Activity
Release Date
December 12, 2024
0.75 Credit
Click to save this course
Psoriasis
CME
FC24: Practical Insights and Pitfalls for Psoriatic Disease in Skin of Color: Early Diagnosis for Effective Treatment: An Online Activity
Release Date
December 12, 2024
Related Media
Powered by Polaris TM
Psoriasis
What are the most important factors to consider when selecting a first-line biologic for patients with psoriasis?Video
Saakshi Khattri
Psoriasis
How does the recommended dosing regimen for ixekizumab compare to those of other biologics for psoriasis?Video
Laura K. Ferris
Psoriasis
How do newer biologic agents like IL-17 inhibitors compare to traditional biologics in psoriasis treatment?Video
Raj Chovatiya